PEER REVIEWED

Electronic Manufacturing Batch Records and Digitalisation in Biopharmaceutical Manufacturing

In response to the evolving expectations of the biopharmaceutical industry, contract manufacturing organisations (CMOs) are facing mounting pressure to optimise processes, uphold data integrity, and scale operations. Traditional paper-based manufacturing batch record (pMBR) practices have become barriers to agility. They limit process visibility, introduce transcription and review errors, and generate bottlenecks that can delay batch release and delivery.

The growing regulatory requirements for ALCOA++ principles, quality, and safety have pushed the industry to transition from paper-based to digitalised record systems, known as electronic batch records, often referred to as electronic manufacturing batch records (eMBRs). Through eMBRs, biomanufacturers can secure data traceability, achieve real-time process oversight, and enable faster, more reliable operations. However, the digital transition has faced roadblocks due to the lack of systematic know-how and expertise.

eMBR systems electronically manage data flow related to operations on the production floor. Unlike paper records that require human transcription, eMBRs interface with various data platforms – enterprise resource planning systems, laboratory information management systems (LIMS), manufacturing execution systems (MES), equipment control systems (distributed control system or individual programmable logic controller), and quality management systems. This interconnectivity enables real-time data flow across business, manufacturing, and quality operations.

Critically, eMBRs support the execution of manufacturing processes step by step through validated, standardised templates. They reinforce procedural adherence, eliminate transcription mistakes, enable immediate access to records, and address key vulnerabilities of paper-based systems. By safeguarding record integrity and providing a robust audit trail, eMBRs generate trustworthy data that meet the expectations of global authorities, such as the U.S. Food and Drug Administration and European Medicines Agency.

Challenges in Traditional Batch Record Management

Historically, pMBR has relied on manual document preparation, change management, and data entry. Operators consult multiple external systems, write down process information on paper, and later transfer the data to other systems. All activities are cross verified, then reviewed by the quality team to ensure integrity. These procedures are time-intensive, error-prone, and dependent on human vigilance.

Several issues consistently challenge traditional batch record practices:

- **Document management:** Numerous batch records are generated during the manufacture of diverse biologics, particularly those that require high-mix, low-volume production. When records are formatted and entered by hand, template changes and operational process adjustments require manual implementation across all pMBRs. This

can lead to inconsistencies, which can complicate management.

- **Inconsistent terminology:** Variations in naming conventions, equipment recipes, units of measure, and language can cause confusion during audits and interdepartmental collaboration.
- **Transcription errors:** The manual copying of data from one source to another increases the chance of human error.
- **Redundant reviews:** Paper records require multiple layers of manual review and sign-off, which prolongs batch record release timelines.
- **Data silos:** When batch records are paper-based, digitising and correlating the myriad data sources becomes difficult, delaying process monitoring and slowing investigations.
- **Regulatory vulnerabilities:** Paper documents are harder to trace, more prone to missing pages, and less secure against unauthorised changes, increasing compliance risks under good manufacturing practice (GMP) frameworks.

The Leading Digital Approach

eMBR systems integrate standardised recipes and real-time data within a validated computerised environment. These digital integrations replace handwritten data entries and manual, paper-based verification with automated, stepwise batch executions.

Standardised eMBR templates encompass all critical process parameters, including raw material details, equipment recipes and tracking, manufacturing instructions, sampling requirements, and deviation management processes. These templates establish uniformity across manufacturing sites, promoting cross-site standardisation and compliance.

By aligning eMBR systems with GMP guidelines, CMOs can address compliance gaps, improving overall batch-to-batch consistency, safety, and operational excellence.

Securing Competitive Advantages with eMBRs

One of the strongest benefits of eMBR integration is enhanced data integrity. eMBR systems capture data in real time, apply role-based access permissions, and generate an unalterable audit trail and activity system log.

Hence, regulatory authorities increasingly prefer digital systems, as they simplify the audit process. With eMBRs, data is easier to retrieve, review, and verify, reducing inspection times and the risk of costly remediation efforts or manufacturing holds.

Human error mitigation is also a key advantage. Without eMBRs, operators would have to refer to pMBRs and manually execute individual equipment recipes, which could lead to misinterpretation or incorrect information being imported from the manufacturing control system monitor. Through eMBRs, instructions are sent directly to each piece of equipment. Batch records are automatically logged with validated data from laboratories or equipment monitoring devices, eliminating the difficulties associated with later reconciling handwritten notes with digital databases.

Moreover, rule-based verification allows for review by exception, where quality teams can focus on investigating flagged events and deviations rather than reviewing hundreds of pages of batch records, associated logbooks, and attachments. As a result, the time spent reviewing batch records significantly decreases, enabling teams to focus entirely on higher-value tasks for continuous improvement and risk mitigation.

In summary, eMBR integration is now imperative for fostering a shift toward a proactive quality oversight culture that goes beyond reactive error correction.

Foundation for Operational Excellence in Biomanufacturing

The eMBR is one of the most adaptable digital tools that can be leveraged for developing and manufacturing a wide range of biologics – monoclonal antibodies, multispecific antibodies, antibody-drug conjugates, Fc fusions, and mRNAs. In addition to unit operations, eMBRs provide a consistent data layer to support uniform data capture, management, and traceability across all stages of the manufacturing process.

The integrated eMBR platform provides opportunities for further integration with advanced technologies, including artificial intelligence (AI), bioprocess digital twins, and real-time process analytical techniques. These future-oriented tools can build upon the eMBR foundation to foster more intelligent and autonomous manufacturing capabilities.

Although eMBR implementation requires an upfront investment in change management, validation, and user training, the long-term payoff is a harmonised, data-rich environment that promotes innovation and scalable growth.

From a process monitoring perspective, eMBRs monitor real-time data and use automated statistical analyses to proactively detect and prevent deviations from process parameters, ensuring consistent performance and product quality.

Quality assurance (QA) teams also benefit from eMBRs through the ability to instantly visualise production data and associated attachments and access to a secure, time-stamped audit trail. As a result, eMBRs simplify deviation investigations, improve traceability, and reduce the time needed to address potential noncompliance.

While laboratory quality control (QC) generally uses LIMS for raw data, eMBRs provide transparency on sample handoffs and drive collaboration among manufacturing, QA, and QC teams. With this digital backbone, there is less reliance on offline communications, fewer missed handoffs, and better alignment on issue resolution.

Addressing Strategic Industry Challenges

For biopharmaceutical companies, a perpetual challenge is the efficient management of time and resources to transition from batch completion to release to ensure long-term business sustainability in the industry. By integrating eMBRs, companies can transform this challenge into a practical and viable opportunity to achieve operational excellence and business success.

When integrated with standardised facility and process designs, eMBRs become robust tools that companies can leverage to streamline operations and secure a competitive edge in the market. eMBR integration eliminates variations in work instructions, process languages, equipment recipes, measurement units, and operations across products and sites.

Automated controls, equipment, and data interfaces that eMBRs bring to the manufacturing floor optimise workforce management. The need for fewer operators enhances efficiency and reduces human variation in process control, leading to improved consistency and quality in operations.

Comprehensive and timely data packages – including material genealogy, equipment logs, and process input and output parameters – ensure that all information is readily available for optimising the batch release process. Easily accessible, structured, and organised data enable a holistic process investigation by comprehensively analysing numerous records. All told, eMBRs establish a robust foundation for continuous manufacturing, a robust quality system, and on-time batch release and delivery.

Strategic Relevance: CMO Competitiveness

For CMOs, adopting eMBRs demonstrates a commitment to data integrity and regulatory compliance.

In an industry where the slightest quality incident can impact patients, advanced digital capabilities become a vital differentiator. These capabilities demonstrate a CMO's readiness to partner with biopharmaceutical companies that expect operational excellence, rapid scaling, and robust compliance.

The biopharmaceutical industry has traditionally taken a conservative approach to production records. However, the growing complexity of biologics, coupled with lessons learned from previous pandemics, has underscored the need for greater supply resilience and highlighted the fragility of paper-based systems. As a result, the trend toward digitalisation, in general, and eMBR adoption, in particular, has gained momentum.

Future Outlook

eMBR systems are expected to integrate even more deeply with advanced MES, rule-based, and AI-driven data review and to offer expanded data connectivity with enterprise data lakes. These future capabilities will support the creation of closed-loop quality management systems, where deviations can be automatically flagged, analysed, and corrected in real time.

Additionally, emerging frameworks, such as digital twins, can build upon eMBRs' data backbone to enable more sophisticated predictive simulations, process optimisation, and continuous improvement.

As regulatory frameworks evolve to accommodate AI and advanced analytics, eMBRs will become a critical component of the digital quality-by-design ecosystem, providing the trusted data required to train and validate predictive process control models while maintaining traceable and compliant oversight.

Broader Impact on the Biopharmaceutical Ecosystem

The benefits of eMBRs extend beyond CMOs' internal operations. Regulatory authorities are increasingly turning to remote or hybrid inspections, where digital access to records supports faster audits. Biopharmaceutical companies gain confidence in supply chain management based on their CMOs' abilities to deliver on schedule with reduced risk of noncompliance.

Ultimately, patients stand to gain the most from eMBR adoption. By minimising errors, eMBRs contribute to a more reliable and resilient drug supply. In therapeutic areas with critical timelines, such as oncology or rare diseases, these improvements mean improved access to life-saving treatments.

eMBR systems lay the foundation for a standardised, harmonised, and data-driven biopharmaceutical manufacturing environment. By championing the eMBR as part of a broader digitalisation strategy, CMOs can position themselves as trusted partners for clients seeking quality, regulatory assurance, and operational excellence.

Bumjoon Cha

Bumjoon Cha is the director of manufacturing science and technology digitalisation at Samsung Biologics. He leads corporate-wide digital transformation initiatives in technical transfer and the commercial management of biopharmaceuticals at the global CDMO. Previously, he was a postdoctoral researcher at the University of Massachusetts, Lowell. Cha holds a Ph.D. in Chemical Engineering from Yonsei University.

Dowan Kim

Dowan Kim, a senior scientist at Samsung Biologics, has over a decade of experience in implementing numerous technology transfer projects at Samsung Biologics. He works as a subject matter expert, developing eMBR systems and strategies for process improvement at the global CDMO. Kim holds a bachelor's degree in Applied Biology & Chemistry from Seoul National University.